Joanna Tracz

Ms. Joanna Tracz

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2021 in Metabolites
Verified
Journal Article
Open access
PDF file
Lukasz MarczakLukasz Marczak
Lukasz Marczak
JIJakub Idkowiak
Jakub Idkowiak
JTJoanna Tracz
Joanna Tracz
MSMaciej Stobiecki
Maciej Stobiecki
BPBartlomiej Perek
Bartlomiej Perek
MLMagdalena Luczak
Magdalena Luczak
Chronic kidney disease (CKD) is characterized by the progressive loss of functional nephrons. Although cardiovascular disease (CVD) complications and atherosclerosis are the leading causes of morbidity and mortality in CKD, the mechanism by which the progression of CVD accelerates remains unclear. To reveal the molecular mechanisms associated with atherosclerosis linked to CKD, we applied a shotgun lipidomics approach fortified with standard laboratory analytical methods and gas chromatography-mass spectrometry technique on selected lipid components and precursors to analyze the plasma lipidome in CKD and classical CVD patients. The MS-based lipidome profiling revealed the upregulation of triacylglycerols in CKD and downregulation of cholesterol/cholesteryl esters, sphingomyelins, phosphatidylcholines, phosphatidylethanolamines and ceramides as compared to CVD group and controls. We have further observed a decreased abundance of seven fatty acids in CKD with strong inter-correlation. In contrast, the level of glycerol was elevated in CKD in comparison to all analyzed groups. Our results revealed the putative existence of a functional causative link—the low cholesterol level correlated with lower estimated glomerular filtration rate and kidney dysfunction that supports the postulated “reverse epidemiology” theory and suggest that the lipidomic background of atherosclerosis-related to CKD is unique and might be associated with other cellular factors, i.e., inflammation.

3 May 2021 in Journal of Proteome Research
Verified
Journal Article
Closed access
JTJoanna Tracz
Joanna Tracz
LHLuiza Handschuh
Luiza Handschuh
MLMaciej Lalowski
Maciej Lalowski
Lukasz MarczakLukasz Marczak
Lukasz Marczak
KKKatarzyna Kostka-Jeziorny
Katarzyna Kostka-Jeziorny
MLMagdalena Luczak
Magdalena Luczak

1 February 2019 in Analytica Chimica Acta
Verified
Journal Article
Closed access
MWMateusz Waliczek
Mateusz Waliczek
RBRemigiusz Bąchor
Remigiusz Bąchor
MKMonika Kijewska
Monika Kijewska
DGDorota Gąszczyk
Dorota Gąszczyk
KPKarolina Panek-Laszczyńska
Karolina Panek-Laszczyńska
PPiotr Stefanowicz
Piotr Stefanowicz

Verified
Journal Article
Open access
PDF file
JTJoanna Tracz
Joanna Tracz
MLMagdalena Luczak
Magdalena Luczak
Patients with chronic kidney disease (CKD) are at increased risk of atherosclerosis and premature mortality, mainly due to cardiovascular events. However, well-known risk factors, which promote “classical” atherosclerosis are alone insufficient to explain the high prevalence of atherosclerosis-related to CKD (CKD-A). The complexity of the molecular mechanisms underlying the acceleration of CKD-A is still to be defied. To obtain a holistic picture of these changes, comprehensive proteomic approaches have been developed including global protein profiling followed by functional bioinformatics analyses of dysregulated pathways. Furthermore, proteomics surveys in combination with other “omics” techniques, i.e., transcriptomics and metabolomics as well as physiological assays provide a solid ground for interpretation of observed phenomena in the context of disease pathology. This review discusses the comprehensive application of various “omics” approaches, with emphasis on proteomics, to tackle the molecular mechanisms underlying CKD-A progression. We summarize here the recent findings derived from global proteomic approaches and underline the potential of utilizing integrative systems biology, to gain a deeper insight into the pathogenesis of CKD-A and other disorders.

1 July 2017 in Journal of Proteomics
Verified
Journal Article
Closed access
Agata ZdartaAgata Zdarta
Agata Zdarta
JTJoanna Tracz
Joanna Tracz
MLM. Luczak
M. Luczak
Urszula GuzikUrszula Guzik
Urszula Guzik
Ewa KaczorekEwa Kaczorek
Ewa Kaczorek

4 June 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
Katarzyna Mazur-MelewskaKatarzyna Mazur-Melewska
Katarzyna Mazur-Melewska
MLMagdalena Luczak
Magdalena Luczak
JTJoanna Tracz
Joanna Tracz
PMPaweł Małecki
Paweł Małecki
Anna ManiaAnna Mania
Anna Mania
MFMagdalena Figlerowicz
Magdalena Figlerowicz
This study investigates the impact of Epstein–Barr virus (EBV) infection on children’s proteomes across different phases of the disease, utilising seventy-nine blood samples categorised into three groups: EBV-naive patients, acute infectious mononucleosis (IM) cases, and convalescents followed up for 12 months post-IM. The aim is to identify proteins influenced by EBV infection, shedding light on the chronic processes triggered by the virus. The results reveal thirty-nine proteins distinguishing between naive patients and those with IM, including actin, lumican, peroxiredoxin-2, fibulin-1, gelsolin, and alpha-2-macroglobulin, which are involved in immune responses, cell adhesion, and inflammation. Elevated oxidative stress markers like peroxiredoxin-2 in IM patients suggest potential links to EBV’s induction of reactive oxygen species. Increased levels of apolipoproteins A-I, A-IV, C-IV, and M during IM imply associations with viral infection, while complement system proteins (C1q, C1r, and C8 gamma chain) are also elevated, reflecting their role in the immune response and viral clearance. This study’s focus on children provides unique insights into EBV’s impact on young populations, emphasising proteomics’ role in uncovering protein associations and understanding the virus’s long-term consequences. However, specific relationships between identified proteins and EBV infection require further investigation.